Bioventus Inc.

Bioventus Inc.

BVSยทNASDAQ

$8.55

+5.4%
HealthcareMedical - Devices

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

At a Glance

Live Snapshot
Market Cap$579.25M
EPS0.3400
P/E Ratio25.15
Earnings Date08/05/2026
3Y-646.0%
5Y+3.0%
10Y+390.0%
3Y-97.0%
5Y-84.0%
10Y-90.0%
3Y-199.0%
5Y+108.0%
10Y+825.0%
BVS

Bioventus Inc. Cash Conversion Engine

BVS ยท NASDAQ
Net Income0.00
Depreciation & Amortization0.00
Stock-Based Compensation0.00
Change in Working Capital-13.84M
Others87.82M
Capital Expenditures-2.56M
Free Cash Flow71.41M

Cash Flow Quality Analysis

CapEx Intensity

3.5%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

+89.0%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

-$13.84M

Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.

Bioventus Inc. Cash Flow Statement

BVS โ€ข NASDAQ

Bioventus Inc. Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2015Dec 2014Dec 2013
OPERATING ACTIVITIES
0.0
-318K
-121.2M
-144.7M
11.5M
14.7M
8.1M
4.4M
-34.1M
-12.9M
-22.4M
0.0
49.6M
57.4M
55.4M
34.9M
28.6M
30.3M
29.2M
33.1M
28.8M
24.5M
0.0
-5.4M
-2.4M
-46.7M
-9.8M
0.0
-348K
-79K
-432K
-701K
-475K
0.0
10.1M
2.7M
17.6M
19.8M
10.1M
0.0
14.3M
0.0
0.0
0.0
87.8M
-3.3M
82M
134.5M
-18.3M
3M
16.2M
-5.6M
31M
11.9M
17.5M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(1.5M)
(1.6M)
(1.9M)
(2.6M)
(785K)
(2.2M)
-13.8M
-11.8M
-3.2M
-29.7M
-15.1M
15.3M
-13.6M
2.9M
-10.6M
-12M
-16.4M
74M
38.8M
15.3M
-13.5M
23M
71.8M
40.7M
45.2M
18.9M
15.1M
2.7M
INVESTING ACTIVITIES
(0.0)
-1M
-7.4M
-1.5M
-13.5M
-16.6M
-2.3M
-6.1M
-2.1M
-1.2M
-6.4M
(0.0)
(0.0)
(34.7M)
(0.0)
-262.9M
(0.0)
(430K)
(0.0)
-51.5M
-10.5M
(0.0)
0.0
0.0
0.0
0.0
0.0
0.0
430K
0.0
0.0
0.0
0.0
-3.2M
24M
-11.5M
-115M
-7.4M
-3.9M
-6.4M
-40K
-6.6M
-19.7M
-4.6M
-3.2M
(23M)
(15.8M)
-116.4M
-283.8M
-20.5M
-7.9M
-6.1M
-60.2M
-31.4M
-11M
FINANCING ACTIVITIES
2.1M
2.4M
778K
5.8M
109.4M
0.0
0.0
0.0
0.0
0.0
0.0
-42.9M
-59.6M
-23.3M
59.6M
166.2M
-10M
-1.4M
-5.3M
-675K
-2.5M
9.3M
(0.0)
(0.0)
(0.0)
(0.0)
-367K
-19.9M
-9.1M
-7.8M
-1M
-2.4M
-2.5M
-20.6M
2.6M
-4.2M
-3.4M
-1.9M
317K
-448K
-160K
32.9M
-1.7M
0.0
-61.4M
-54.6M
-26.7M
62.1M
273.4M
-29.6M
-11M
-13.3M
31.2M
-6.6M
6.8M
CASH FLOW SUMMARY
371K
-2.6M
629K
521K
-228K
589K
-104K
-160K
-805K
-1.4M
-514K
9.7M
4.6M
5.1M
-67.4M
12.4M
22.3M
21.7M
25.7M
-10.8M
-24.3M
-2M
41.6M
37M
31.8M
99.2M
86.8M
64.5M
42.8M
17.1M
15.8M
40.1M
42.1M
51.2M
41.6M
37M
31.8M
99.2M
86.8M
64.5M
42.8M
5M
15.8M
40.1M
71.4M
37.8M
8M
-15M
2.1M
51.1M
32.4M
39.1M
11.5M
-5.7M
-3.6M

SEC Filings

BVS - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 21, 2026
May 21, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 06, 2026
March 28, 2026
2026
8-K

8-K 2026

N/A

May 06, 2026
May 06, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 22, 2026
December 31, 2025
2025
10-K

10-K 2025 FY

FY

March 05, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

March 05, 2026
March 05, 2026
2026
8-K

8-K 2025

N/A

November 17, 2025
November 14, 2025
2025
10-Q

10-Q 2025 Q3

Q3

November 04, 2025
September 27, 2025
2025
8-K

8-K 2025

N/A

November 04, 2025
November 04, 2025
2025
8-K

8-K 2025

N/A

August 06, 2025
August 06, 2025
2025
Showing 1 to 10 of 108 filings